V2 sact_regimen
781,388 rows · 12 columns
| ENCORE_PATIENT_ID | MERGED_REGIMEN_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | BENCHMARK_GROUP | LINK_NUMBER |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 10423209 | 10041409 | 1.51 | 69 | Adjuvant (A) | 2019-03-02 | 2019-03-04 | ABVD | N | N | CISPLATIN + RT | 100991386 |
| 10423278 | 10041410 | 1.7 | 84.05 | Neo-adjuvant (N) | 2021-06-16 | 2021-06-16 | GEMCITABINE + OXALIPLATIN + RITUXIMAB | 02 | N | LETROZOLE + PALBOCICLIB | 101468386 |
| 10423284 | 10041411 | 1.74 | 91.4 | null | 2022-05-28 | 2022-05-29 | GO2 TRIAL | 02 | null | APALUTAMIDE | 100534484 |
| 10423291 | 10041412 | null | null | null | 2021-03-26 | 2021-03-27 | CAPECITABINE + PACLITAXEL | 02 | null | BORTEZOMIB + DARATUMUMAB + THALIDOMIDE | 100955850 |
| 10423391 | 10041415 | null | null | Palliative (P) | 2018-10-05 | 2018-10-05 | ATEZOLIZUMAB + CARBOPLATIN + ETOPOSIDE | 02 | null | FLAG + IDARUBICIN | 100703878 |
| 10423408 | 10041416 | 1.8 | 82 | Curative (C) | 2019-05-08 | 2019-05-08 | ATG | N | N | DOXORUBICIN | 101443785 |
| 10423496 | 10041418 | 1.57 | 77.3 | Palliative (P) | 2013-01-07 | 2019-01-06 | GEMCITABINE + PACLITAXEL ALBUMIN (ABRAXANE) | 02 | N | SORAFENIB | 100207489 |
| 10423503 | 10041419 | 1.61 | 82 | Palliative (P) | 2020-01-09 | 2020-01-21 | PACLITAXEL + TRASTUZUMAB | 01 | null | CYCLOPHOSPHAMIDE | 101596273 |
| 10423523 | 10041420 | 1.8 | 85.7 | Curative (C) | 2018-06-17 | 2018-06-24 | AML 18 TRIAL | 02 | N | CETUXIMAB + FLUOROURACIL + IRINOTECAN | 100757988 |
| 10423577 | 10041423 | 1.69 | 67.6 | Palliative (P) | 2016-06-08 | 2016-06-15 | Letrozole + Palbociclib | 02 | N | BORTEZOMIB + DARATUMUMAB | 101427066 |
| 10423604 | 10041425 | null | null | Palliative (P) | 2020-04-20 | 2020-04-20 | PEGINTERFERON ALFA | 02 | N | CARBOPLATIN + LIPOSOMAL DOX | 100206028 |
| 10423638 | 10041426 | null | 91 | null | 2017-08-02 | 2017-08-02 | Irinotecan + Modified De Gramont | 01 | null | OSIMERTINIB | 101611104 |
| 10423692 | 10041428 | 1.62 | 48.8 | 03 | 2017-09-12 | 2017-10-02 | Ipilimumab | null | null | BORTEZOMIB + PANOBINOSTAT | 101865797 |
| 10423791 | 10041429 | 0 | 55.65 | Neo-adjuvant (N) | null | 2017-11-30 | Cisplatin + Pembrolizumab + Pemetrexed | N | N | CVD | 100892916 |
| 10423892 | 10041430 | null | 59.8 | Curative (C) | 2019-08-03 | 2019-08-15 | MATRIX (lymphoma) | 02 | null | IPILIMUMAB | 100852403 |
| 10423962 | 10041431 | 1.54 | 82 | Curative (C) | 2017-03-27 | 2017-04-11 | Abemaciclib | 02 | N | EOX | 100629777 |
| 10423965 | 10041432 | 1.72 | 78 | null | 2019-08-21 | 2019-09-10 | CYCLOPHOSPHAMIDE + LENALIDOMIDE | 02 | null | PENTOSTATIN | 100092178 |
| 10424062 | 10041433 | 1.85 | 94 | Not known (9) | 2021-05-05 | 2021-05-12 | BUSULFAN | 02 | null | LIPOSOMAL DAUNORUBICIN + LIPOSOMAL CYTARABINE (VYXEOS) | 100890552 |
| 10424086 | 10041434 | 1.6 | 0 | null | 2017-01-18 | 2017-01-30 | Sorafenib | 02 | null | BORTEZOMIB + MELPHALAN | 100084528 |
| 10424134 | 10041437 | 1.74 | 68 | null | 2018-10-09 | 2018-10-19 | Myeloma XV Trial | 02 | null | OBINUTUZUMAB + VENETOCLAX | 100350432 |
| 10424156 | 10041438 | 1.77 | 100.9 | 03 | 2014-11-24 | 2015-05-01 | AZACITIDINE + VENETOCLAX | 02 | N | CYCLOPHOSPHAMIDE + OBINUTUZUMAB + VINCRISTINE | 100838723 |
| 10424217 | 10041440 | 1.75 | 80 | null | 2021-10-21 | 2021-12-03 | Apalutamide | 02 | null | CARBOPLATIN + DOCETAXEL + PERTUZUMAB + TRASTUZUMAB | 100797611 |
| 10424249 | 10041441 | 1.58 | 83 | null | 2018-01-19 | 2018-01-21 | CHLVPP | 02 | null | GEMCARBO | 101457484 |
| 10424251 | 10041442 | 1.77 | 74.1 | Palliative (P) | 2015-12-01 | 2015-12-28 | Doxorubicin + Olaratumab | N | null | CISPLATIN + RT | 100208898 |
| 10424336 | 10041445 | 1.69 | 73.8 | 03 | null | 2019-06-05 | MYELOMA XIV TRIAL | null | N | BORTEZOMIB + DARATUMUMAB | 101697073 |
| 10424518 | 10041446 | 1.53 | 39 | Neo-adjuvant (N) | 2019-09-19 | 2019-09-19 | Cyclophosphamide + Docetaxel + Trastuzumab | N | null | LETROZOLE + PALBOCICLIB | 100596855 |
| 10424565 | 10041447 | 1.65 | 66 | null | 2020-11-03 | 2020-11-18 | AVAPRITINIB | 02 | null | ISATUXIMAB + POMALIDOMIDE | 101084901 |
| 10424593 | 10041448 | 1.63 | null | Palliative (P) | 2016-09-29 | 2016-10-01 | null | 02 | N | CARBOPLATIN + DOXORUBICIN + MITOMYCIN | 101145112 |
| 10424900 | 10041450 | 1.82 | 0 | Palliative (P) | 2019-10-16 | 2019-10-27 | Doxorubicin + Olaratumab | N | null | BINIMETINIB + ENCORAFENIB | 100993310 |
| 10424951 | 10041451 | 1.83 | 70.8 | Palliative (P) | 2018-05-04 | 2018-05-13 | Cisplatin + Pemetrexed | 02 | null | CYCLOPHOSPHAMIDE + LENALIDOMIDE | 101757735 |
| 10424962 | 10041452 | 0 | 0 | 03 | 2017-09-05 | 2017-09-06 | FCR Oral - Cycle 1 | 02 | N | BENDAMUSTINE + OBINUTUZUMAB | 100264363 |
| 10425011 | 10041454 | 0 | 81.25 | Palliative (P) | 2018-11-28 | 2018-12-04 | ABEMACICLIB + FULVESTRANT | 02 | N | AML17 TRIAL | 100617632 |
| 10425183 | 10041458 | 1.62 | 93.4 | 03 | 2019-04-23 | 2019-05-04 | Capecitabine (21days) + Carboplatin | 02 | N | OSIMERTINIB | 100061842 |
| 10425199 | 10041459 | 1.72 | 61.6 | 03 | 2018-03-16 | 2018-03-18 | CETUXIMAB + RT | 02 | N | LANREOTIDE | 100259779 |
| 10425259 | 10041460 | 1.7 | 78 | 03 | 2019-03-09 | 2019-03-22 | null | N | null | AZACITIDINE + VENETOCLAX | 100134991 |
| 10425272 | 10041462 | 1.82 | 69.4 | Curative (C) | 2017-05-27 | 2017-06-27 | CISPLATIN + GEMCITABINE + RITUXIMAB | null | N | MYELOMA XIV TRIAL | 100998880 |
| 10425303 | 10041463 | 1.53 | 86 | Curative (C) | 2018-11-20 | 2018-11-20 | null | Y | null | CYCLOPHOSPHAMIDE + DOCETAXEL + EPIRUBICIN | 100196453 |
| 10425324 | 10041464 | 1.7 | 74.7 | 03 | 2017-02-27 | 2017-02-27 | Cladribine + Rituximab | 02 | N | FLAG + IDARUBICIN | 100027483 |
| 10425354 | 10041467 | 1.63 | null | null | 2019-09-05 | 2019-09-07 | MPV | N | Y | AFATINIB | 100309174 |
| 10425359 | 10041468 | 1.53 | 74.3 | Palliative (P) | 2016-09-25 | 2016-10-31 | ETOPOSIDE | N | N | GEMCARBO | 100862590 |
| 10425369 | 10041469 | 1.71 | 76.2 | null | 2021-06-28 | 2021-07-09 | CETUXIMAB + IRINOTECAN + MDG | N | Y | CYCLOPHOSPHAMIDE + FLUDARABINE + RITUXIMAB | 101696731 |
| 10425486 | 10041470 | 1.61 | 63.2 | Adjuvant (A) | 2019-09-05 | 2019-09-05 | DOXORUBICIN | 02 | N | PATHOS TRIAL | 101374041 |
| 10425497 | 10041471 | 1.75 | 67.7 | Curative (C) | 2019-03-04 | 2019-03-06 | LANREOTIDE | null | N | APALUTAMIDE | 100315768 |
| 10425500 | 10041472 | 1.62 | 69.9 | null | 2021-09-01 | 2021-09-01 | Apalutamide | 02 | null | BENDAMUSTINE + OBINUTUZUMAB | 101371772 |
| 10425550 | 10041474 | 1.68 | 77 | Palliative (P) | 2019-06-05 | 2019-06-13 | CETUXIMAB + RT | 02 | N | FLUOROURACIL + MITOMYCIN + RT | 101617849 |
| 10425582 | 10041475 | 1.67 | 67.2 | Palliative (P) | 2019-08-01 | 2019-09-07 | RIALTO TRIAL | 02 | N | CYCLOPHOSPHAMIDE + LENALIDOMIDE | 100515361 |
| 10425586 | 10041476 | 1.77 | 108.4 | Neo-adjuvant (N) | 2022-04-15 | 2022-04-17 | ECX | N | null | CARBOPLATIN + PACLITAXEL + PEMBROLIZUMAB | 100277782 |
| 10425714 | 10041480 | 1.52 | 78.4 | null | 2021-09-01 | 2021-09-05 | Fulvestrant + Palbociclib | 02 | null | CLARITY TRIAL | 100612156 |
| 10425742 | 10041481 | 1.67 | 102 | Neo-adjuvant (N) | 2019-01-02 | 2019-01-02 | Vinorelbine (oral) | 02 | N | BORTEZOMIB + RITUXIMAB | 101324934 |
| 10425756 | 10041482 | 1.85 | 57.55 | Palliative (P) | 2016-10-20 | 2016-10-25 | TCH (21 day Trastuzumab) Loading | 02 | N | CAPECITABINE + TEMOZOLOMIDE | 101823640 |